Citations (59)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
BM Turner & DG Hicks. (2017) Pathologic diagnosis of breast cancer patients: evolution of the traditional clinical-pathologic paradigm toward “precision” cancer therapy. Biotechnic & Histochemistry 92:3, pages 175-200.
Read now
Read now
Dg Hicks & B Turner. (2015) Pathologic diagnosis, immunohistochemistry, multigene assays and breast cancer treatment: progress toward “precision” cancer therapy. Biotechnic & Histochemistry 90:2, pages 81-92.
Read now
Read now
Malcolm D. Mattes, Justin M. Mann, Hani Ashamalla & Ajay Tejwani. (2013) Routine Histopathologic Characteristics Can Predict Oncotype DXTM Recurrence Score in Subsets of Breast Cancer Patients. Cancer Investigation 31:9, pages 604-606.
Read now
Read now
Articles from other publishers (56)
Hee Jeong Kim, Woo Jung Choi, Joo Hee Cha, Hee Jung Shin, Eun Young Chae & Hak Hee Kim. (2023) Prediction of the MammaPrint risk group using MRI features in women with estrogen receptor-positive, HER2-negative, and 1–3 node-positive invasive breast cancer. Clinical Breast Cancer.
Crossref
Crossref
Youngji Kwak, Sung Yoon Jang, Joon Young Choi, Hyunjun Lee, Dong Seung Shin, Yeon Hee Park, Ji-Yeon Kim, Jin-Seok Ahn, Byung Joo Chae, Jonghan Yu, Jeong Eon Lee, Seok Won Kim, Seok Jin Nam & Jai Min Ryu. (2023) Progesterone Receptor Expression Level Predicts Prognosis of Estrogen Receptor-Positive/HER2-Negative Young Breast Cancer: A Single-Center Prospective Cohort Study. Cancers 15:13, pages 3435.
Crossref
Crossref
Shichao Zhang, Yan Liu, Xu Liu, Yingxue Liu & Jin Zhang. (2023) Prognoses of Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy before Surgery: A Retrospective Analysis. Cancers 15:4, pages 1157.
Crossref
Crossref
Bradley M. Turner, Brian S. Finkelman, David G. Hicks, Numbere Numbereye, Ioana Moisini, Ajay Dhakal, Kristin Skinner, Mary Ann G. Sanders, Xi Wang, Michelle Shayne, Linda Schiffhauer, Hani Katerji & Huina Zhang. (2023) The Rochester Modified Magee Algorithm (RoMMa): An Outcomes Based Strategy for Clinical Risk-Assessment and Risk-Stratification in ER Positive, HER2 Negative Breast Cancer Patients Being Considered for Oncotype DX® Testing. Cancers 15:3, pages 903.
Crossref
Crossref
Hongxiao Li, Jigang Wang, Zaibo Li, Melad Dababneh, Fusheng Wang, Peng Zhao, Geoffrey H. Smith, George Teodoro, Meijie Li, Jun Kong & Xiaoxian Li. (2022) Deep Learning-Based Pathology Image Analysis Enhances Magee Feature Correlation With Oncotype DX Breast Recurrence Score. Frontiers in Medicine 9.
Crossref
Crossref
Anna Diana, Francesca Carlino, Giuseppe Buono, Giuliano Antoniol, Vincenzo Famiglietti, Carmine De Angelis, Simone Carrano, Antonio Piccolo, Ferdinando De Vita, Fortunato Ciardiello, Bruno Daniele, Grazia Arpino & Michele Orditura. (2022) Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis. Frontiers in Oncology 12.
Crossref
Crossref
Young Joo Lee, Young Sol Hwang, Junetae Kim, Sei-Hyun Ahn, Byung Ho Son, Hee Jeong Kim, Beom Seok Ko, Jisun Kim, Il Yong Chung, Jong Won Lee & Sae Byul Lee. (2021) A nomogram for predicting probability of low risk of MammaPrint results in women with clinically high-risk breast cancer. Scientific Reports 11:1.
Crossref
Crossref
Ning Mao, Ping Yin, Haicheng Zhang, Kun Zhang, Xicheng Song, Dong Xing & Tongpeng Chu. (2021) Mammography-based radiomics for predicting the risk of breast cancer recurrence: a multicenter study. The British Journal of Radiology 94:1127.
Crossref
Crossref
Akisha Glasgow, Haley Sechrist, Phillip Bomeisl, Hannah Gilmore & Aparna Harbhajanka. (2020) Correlation between modified Magee equation-2 and Oncotype-Dx recurrence scores using both traditional and TAILORx cutoffs and the clinical application of the Magee Decision Algorithm: a single institutional review. Breast Cancer 28:2, pages 321-328.
Crossref
Crossref
Brandon S. Nichols, Erika Chelales, Roujia Wang, Amanda Schulman, Jennifer Gallagher, Rachel A. Greenup, Joseph Geradts, Josephine Harter, Paul K. Marcom, Lee G. Wilke & Nirmala Ramanujam. (2020) Quantitative assessment of distant recurrence risk in early stage breast cancer using a nonlinear combination of pathological, clinical and imaging variables. Journal of Biophotonics 13:10.
Crossref
Crossref
Aline Baltres, Zeina Al Masry, Ryad Zemouri, Severine Valmary-Degano, Laurent Arnould, Noureddine Zerhouni & Christine Devalland. (2020) Prediction of Oncotype DX recurrence score using deep multi-layer perceptrons in estrogen receptor-positive, HER2-negative breast cancer. Breast Cancer 27:5, pages 1007-1016.
Crossref
Crossref
Rohit Bhargava, Beth Z. Clark, Gloria J. Carter, Adam M. Brufsky & David J. Dabbs. (2020) The healthcare value of the Magee Decision Algorithm™: use of Magee Equations™ and mitosis score to safely forgo molecular testing in breast cancer. Modern Pathology 33:8, pages 1563-1570.
Crossref
Crossref
Shin Hye Yoo, Tae-Yong Kim, Miso Kim, Kyung-Hun Lee, Eunshin Lee, Han-Byoel Lee, Hyeong-Gon Moon, Wonshik Han, Dong-Young Noh, Sae-Won Han, Tae-You Kim & Seock-Ah Im. (2020) Development of a Nomogram to Predict the Recurrence Score of 21-Gene Prediction Assay in Hormone Receptor–Positive Early Breast Cancer. Clinical Breast Cancer 20:2, pages 98-107.e1.
Crossref
Crossref
Abdulmohsen Alkushi, Ahmad Omair, Haitham Arabi, Emad Masuadi & Omalkhair Abualkhair. (2020) Predictability of 21-Gene Recurrence Score Assay by Using Pathological and Immunohistochemical Parameters in Breast Cancer. Breast Cancer: Basic and Clinical Research 14, pages 117822342097784.
Crossref
Crossref
Bradley M. Turner, Mary Ann Gimenez‐Sanders, Armen Soukiazian, Andrea C. Breaux, Kristin Skinner, Michelle Shayne, Nyrie Soukiazian, Marilyn Ling & David G. Hicks. (2019)
Risk stratification of ER‐positive breast cancer patients: A multi‐institutional validation and outcome study of the Rochester Modified Magee algorithm (RoMMa) and prediction of an Oncotype DX
®
recurrence score <26
. Cancer Medicine 8:9, pages 4176-4188.
Crossref
Crossref
Sae Byul Lee, Junetae Kim, Guiyun Sohn, Jisun Kim, Il Yong Chung, Hee Jeong Kim, Beom Seok Ko, Byung Ho Son, Sei-Hyun Ahn, Jong Won Lee & Kyung Hae Jung. (2019) A Nomogram for Predicting the Oncotype DX Recurrence Score in Women with T1-3N0-1miM0 Hormone Receptor‒Positive, Human Epidermal Growth Factor 2 (HER2)‒Negative Breast Cancer. Cancer Research and Treatment 51:3, pages 1073-1085.
Crossref
Crossref
Martin Mutonga, Sedona Speedy, Alfred Rademaker, Dachao Liu, Regina Uthe, Sarika Jain, William J. Gradishar, Lisa Flaum & Cesar A. Santa-Maria. (2019) Relationship of pathological features and a 21 gene expression assay in younger versus older women with node-negative endocrine receptor-positive breast cancer. Breast Cancer Research and Treatment 176:1, pages 95-100.
Crossref
Crossref
Claudio Ceccarelli, Antonio De Leo, Pasquale Chieco, Claudio Zamagni, Alice Zamagni, Daniela Rubino, Mario Taffurelli & Donatella Santini. (2019) A simple immunohistochemical bio-profile incorporating Bcl2 curbs those cases of invasive breast carcinoma for which an Oncotype Dx characterization is needed. PLOS ONE 14:6, pages e0217937.
Crossref
Crossref
Susan J. Robertson, Mohammed F.K. Ibrahim, Carol Stober, John Hilton, Zuzana Kos, Sasha Mazzarello, Tim Ramsay, Dean Fergusson, Lisa Vandermeer, Ranjeeta Mallick, Angel Arnaout, Susan F. Dent, Roanne Segal, Sandeep Sehdev, Stan Gertler, Brian Hutton & Mark Clemons. (2019) Does integration of Magee equations into routine clinical practice affect whether oncologists order the Oncotype DX test? A prospective randomized trial. Journal of Evaluation in Clinical Practice 25:2, pages 196-204.
Crossref
Crossref
Rohit Bhargava, Beth Z Clark & David J Dabbs. (2019) Breast Cancers With Magee Equation Score of Less Than 18, or 18-25 and Mitosis Score of 1, Do Not Require Oncotype DX Testing. American Journal of Clinical Pathology 151:3, pages 316-323.
Crossref
Crossref
Anne Grabenstetter, Edi Brogi, Joanne F. Chou, Monica Morrow, Maura Dickler, Larry Norton & Hannah Y. Wen. (2018) Multifocal/Multicentric Ipsilateral Invasive Breast Carcinomas with Similar Histology: Is Multigene Testing of All Individual Foci Necessary?. Annals of Surgical Oncology 26:2, pages 329-335.
Crossref
Crossref
Ali Atashab Parvar, Sara Salari Baghoon Abad, Toba Abbasi & Elham Boushehri. (2019) Correlation of Allred Score with Tumor Behavior in Breast Cancer Patients Referred to Shahid-Mohammadi Hospital From 2010 to 2017. Hormozgan Medical Journal In Press:In Press.
Crossref
Crossref
Mark D. Zarella, Rebecca C. Heintzelman, Nikolay K. Popnikolov & Fernando U. Garcia. (2018) BCL-2 expression aids in the immunohistochemical prediction of the Oncotype DX breast cancer recurrence score. BMC Clinical Pathology 18:1.
Crossref
Crossref
Jai Min Ryu, Hee Jun Choi, Isaac Kim, Se Kyung Lee, Jonghan Yu, Jee-Eun Kim, Byeong-il Kang, Jeong Eon Lee, Seok Jin Nam & Seok Won Kim. (2018) Only estrogen receptor “positive” is not enough to predict the prognosis of breast cancer. Breast Cancer Research and Treatment 172:3, pages 627-636.
Crossref
Crossref
David J Dabbs, Beth Z Clark, Kate Serdy, Agnieszka Onisko, Adam M Brufsky, Sherie Smalley, Stephen Perkins & Rohit Bhargava. (2018)
Pathologist's health-care value in the triage of Oncotype DX
®
testing: a value-based pathology study of tumour biology with outcomes
. Histopathology 73:4, pages 692-700.
Crossref
Crossref
Maher Sughayer, Rolla Alaaraj & Ahmad Alsughayer. (2018) Applying new Magee equations for predicting the Oncotype Dx recurrence score. Breast Cancer 25:5, pages 597-604.
Crossref
Crossref
Hans-Ullrich Voelker, Lea Frey, Annette Strehl & Michael Weigel. (2018) Practical Consequences Resulting from the Analysis of a 21-Multigene Array in the Interdisciplinary Conference of a Breast Cancer Center. International Journal of Breast Cancer 2018, pages 1-8.
Crossref
Crossref
Ko Un Park, Yalei Chen, Dhananjay Chitale, Sarah Choi, Haythem Ali, S. David Nathanson, Jessica Bensenhaver, Erica Proctor, Lindsay Petersen, Randa Loutfi, Alyson Simonds, Marcia Kuklinski, Thomas Doyle, Vrushali Dabak, Kim Cole, Melissa Davis & Lisa Newman. (2018) Utilization of the 21-Gene Recurrence Score in a Diverse Breast Cancer Patient Population: Development of a Clinicopathologic Model to Predict High-Risk Scores and Response to Neoadjuvant Chemotherapy. Annals of Surgical Oncology 25:7, pages 1921-1927.
Crossref
Crossref
Ashirbani Saha, Michael R. Harowicz, Weiyao Wang & Maciej A. Mazurowski. (2018) A study of association of Oncotype DX recurrence score with DCE-MRI characteristics using multivariate machine learning models. Journal of Cancer Research and Clinical Oncology 144:5, pages 799-807.
Crossref
Crossref
Daniel J Farrugia, Alessandra Landmann, Li Zhu, Emilia J Diego, Ronald R Johnson, Marguerite Bonaventura, Atilla Soran, David J Dabbs, Beth Z Clark, Shannon L Puhalla, Rachel C Jankowitz, Adam M Brufsky, Barry C Lembersky, Gretchen M Ahrendt, Priscilla F McAuliffe & Rohit Bhargava. (2017) Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors. Modern Pathology 30:8, pages 1078-1085.
Crossref
Crossref
Yanjun Hou, Gary Tozbikian, Debra L. Zynger & Zaibo Li. (2017) Using the Modified Magee Equation to Identify Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay (Oncotype DX Assay). American Journal of Clinical Pathology 147:6, pages 541-548.
Crossref
Crossref
Amila Orucevic, John L. Bell, Alison P. McNabb & Robert E. Heidel. (2017) Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data. Breast Cancer Research and Treatment 163:1, pages 51-61.
Crossref
Crossref
Michael R. Harowicz, Timothy J. Robinson, Michaela A. Dinan, Ashirbani Saha, Jeffrey R. Marks, P. Kelly Marcom & Maciej A. Mazurowski. (2017) Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset. Breast Cancer Research and Treatment 162:1, pages 1-10.
Crossref
Crossref
Matthew G. Hanna, Ira J. Bleiweiss, Anupma Nayak & Shabnam Jaffer. (2017) Correlation of Oncotype DX Recurrence Score with Histomorphology and Immunohistochemistry in over 500 Patients. International Journal of Breast Cancer 2017, pages 1-6.
Crossref
Crossref
Giancarlo Pruneri & Francesca Boggio. 2017. Breast Cancer. Breast Cancer
121
131
.
Hyun-seok KimChristopher B. UmbrichtPeter B. IlleiAshley Cimino-MathewsSoonweng ChoNivedita ChowdhuryMaria Cristina Figueroa-MagalhaesCatherine PesceStacie C. JeterCharles MylanderMartin RosmanLorraine TafraBradley M. TurnerDavid G. HicksTyler A. JensenDylan V. MillerDeborah K. ArmstrongRoisin M. ConnollyJohn H. FettingRobert S. MillerBen Ho ParkVered StearnsKala VisvanathanAntonio C. WolffLeslie Cope. (2016) Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer. Journal of Clinical Oncology 34:36, pages 4390-4397.
Crossref
Crossref
Richard R. Love. (2016) On the road to precision, there is more practical medicine to be implemented. The Breast 29, pages 188-191.
Crossref
Crossref
Ping Tang & Gary M. Tse. (2016) Immunohistochemical Surrogates for Molecular Classification of Breast Carcinoma: A 2015 Update. Archives of Pathology & Laboratory Medicine 140:8, pages 806-814.
Crossref
Crossref
Vandana Dialani, Shantanu Gaur, Tejas S. Mehta, Shambhavi Venkataraman, Valerie Fein-Zachary, Jordana Phillips, Alexander Brook & Priscilla J. Slanetz. (2016) Prediction of Low versus High Recurrence Scores in Estrogen Receptor–Positive, Lymph Node–Negative Invasive Breast Cancer on the Basis of Radiologic-Pathologic Features: Comparison with Oncotype DX Test Recurrence Scores. Radiology 280:2, pages 370-378.
Crossref
Crossref
Lubna N. Chaudhary, Zeeshan Jawa, Aniko Szabo, Alexis Visotcky & Christopher R. Chitambar. (2016) Relevance of progesterone receptor immunohistochemical staining to Oncotype DX recurrence score. Hematology/Oncology and Stem Cell Therapy 9:2, pages 48-54.
Crossref
Crossref
Yoshio Mizuno, Hiromi Fuchikami, Naoko Takeda, Junichi Yamada, Yuko Inoue, Hiroshi Seto & Kazuhiko Sato. (2016) Comparing Oncotype DX Recurrence Score Categories with Immunohistochemically Defined Luminal Subtypes. Journal of Cancer Therapy 07:03, pages 223-231.
Crossref
Crossref
David G. Hicks & Susan C. Lester. 2016. Diagnostic Pathology: Breast. Diagnostic Pathology: Breast
386
393
.
Michele M. Gage, Martin Rosman, W. Charles Mylander, Erica Giblin, Hyun-seok Kim, Leslie Cope, Christopher Umbricht, Antonio C. Wolff & Lorraine Tafra. (2015) A Validated Model for Identifying Patients Unlikely to Benefit From the 21-Gene Recurrence?Score Assay. Clinical Breast Cancer 15:6, pages 467-472.
Crossref
Crossref
Elisabeth Luporsi, Jean-Pierre Bellocq, Jérôme Barrière, Julia Bonastre, Jérôme Chetritt, Anne-Gaëlle Le Corroller, Patricia de Cremoux, Frédéric Fina, Anne-Sophie Gauchez, Pierre-Jean Lamy, Pierre-Marie Martin, Chafika Mazouni, Jean-Philippe Peyrat, Gilles Romieu, Laetitia Verdoni, Valérie Mazeau-Woynar & Diana Kassab-Chahmi. (2015) uPA/PAI-1, Oncotype DX™, MammaPrint®. Valeurs pronostique et prédictive pour une utilité clinique dans la prise en charge du cancer du sein. Bulletin du Cancer 102:9, pages 719-729.
Crossref
Crossref
Bradley M Turner, Kristin A Skinner, Ping Tang, Mary C Jackson, Nyrie Soukiazian, Michelle Shayne, Alissa Huston, Marilyn Ling & David G Hicks. (2015) Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score. Modern Pathology 28:7, pages 921-931.
Crossref
Crossref
Zhang Zhang, Jianmin Wang, Kristin A Skinner, Michelle Shayne, Steven I Hajdu, Hong Bu, David G Hicks & Ping Tang. (2014) Pathological features and clinical outcomes of breast cancer according to levels of oestrogen receptor expression. Histopathology 65:4, pages 508-516.
Crossref
Crossref
Linda P Feeley, Anna M Mulligan, Dushanthi Pinnaduwage, Shelley B Bull & Irene L Andrulis. (2014) Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information. Modern Pathology 27:4, pages 554-561.
Crossref
Crossref
E. Luporsi, J. P. Bellocq, J. Barrière, J. Bonastre, J. Chetritt, A. G. Le Corroller, P. de Cremoux, F. Fina, A. S. Gauchez, P. J. Lamy, P. M. Martin, C. Mazouni, J. P. Peyrat, G. Romieu, L. Verdoni, V. Mazeau-Woynar & D. Kassab-Chahmi. (2014) uPA/PAI-1, Oncotype DX™, MammaPrint® Valeurs pronostique et prédictive pour une utilité clinique dans la prise en charge du cancer du seinuPA/PAI-1, Oncotype DX™, MammaPrint® Prognosis and predictive values for clinical utility in breast cancer management. Oncologie 16:4, pages 196-206.
Crossref
Crossref
Helen Ingoldsby, Mark Webber, Deirdre Wall, Carl Scarrott, John Newell & Grace Callagy. (2013) Prediction of Oncotype DX and TAILORx risk categories using histopathological and immunohistochemical markers by classification and regression tree (CART) analysis. The Breast 22:5, pages 879-886.
Crossref
Crossref
Molly E Klein, David J Dabbs, Yongli Shuai, Adam M Brufsky, Rachel Jankowitz, Shannon L Puhalla & Rohit Bhargava. (2013) Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis. Modern Pathology 26:5, pages 658-664.
Crossref
Crossref
James A Kraus, David J Dabbs, Sushil Beriwal & Rohit Bhargava. (2012) Semi-quantitative immunohistochemical assay versus oncotype DX® qRT-PCR assay for estrogen and progesterone receptors: an independent quality assurance study. Modern Pathology 25:6, pages 869-876.
Crossref
Crossref
Geza Acs, Nicole N Esposito, John Kiluk, Loretta Loftus & Christine Laronga. (2012) A mitotically active, cellular tumor stroma and/or inflammatory cells associated with tumor cells may contribute to intermediate or high Oncotype DX Recurrence Scores in low-grade invasive breast carcinomas. Modern Pathology 25:4, pages 556-566.
Crossref
Crossref
Mary Jo Lund, Marina Mosunjac, Kelly M. Davis, Sheryl Gabram‐Mendola, Monica Rizzo, Harvey L. Bumpers, Sherita Hearn, Amelia Zelnak, Toncred Styblo & Ruth M. O'Regan. (2011) 21‐Gene recurrence scores. Cancer 118:3, pages 788-796.
Crossref
Crossref
K. H. Allison, P. L. Kandalaft, C. M. Sitlani, S. M. Dintzis & A. M. Gown. (2011) Routine pathologic parameters can predict Oncotype DXTM recurrence scores in subsets of ER positive patients: who does not always need testing?. Breast Cancer Research and Treatment 131:2, pages 413-424.
Crossref
Crossref
Jenny J. Lee & Jeannie Shen. (2020)
Is the Oncotype DX Assay Necessary in Strongly Estrogen Receptor-Positive Breast Cancers?
. The American Surgeon 77:10, pages 1364-1367.
Crossref
Crossref
S Sahebjam, R Aloyz, D Pilavdzic, M-L Brisson, C Ferrario, N Bouganim, V Cohen, W H Miller & L C Panasci. (2011) Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score. British Journal of Cancer 105:9, pages 1342-1345.
Crossref
Crossref